HM15912 Active for Short Bowel Syndrome

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Short Bowel Syndrome+1 More
HM15912 Active - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug for safety, how it is processed by the body, and how it affects people with a specific intestinal disorder.

Eligible Conditions
  • Short Bowel Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Short Bowel Syndrome

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: for 24 weeks

for 24 weeks
Incidence of adverse events (AEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Short Bowel Syndrome

Trial Design

4 Treatment Groups

HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active
1 of 4
HM15912 0.5 mg/kg Active
1 of 4
Matching Placebo
1 of 4
Placebo
1 of 4
Experimental Treatment
Non-Treatment Group

18 Total Participants · 4 Treatment Groups

Primary Treatment: HM15912 Active · Has Placebo Group · Phase 2

HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active
Drug
Experimental Group · 1 Intervention: HM15912 Active · Intervention Types: Drug
HM15912 0.5 mg/kg Active
Drug
Experimental Group · 1 Intervention: HM15912 Active · Intervention Types: Drug
Matching Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: for 24 weeks

Who is running the clinical trial?

Hanmi Pharmaceutical Company LimitedLead Sponsor
179 Previous Clinical Trials
59,647 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
People who are 18 years of age or older and have intestinal failure that results in short bowel syndrome (SBS) are able to sign an informed consent form.
They are able to give their consent which is in agreement with the information given in the ICF and this protocol.
The study is looking for patients with short bowel syndrome who have had a recent intestinal resection and have been stable regarding their need for intravenous or parenteral nutrition for at least six months

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.